On January 2, 2018 Alexion Pharmaceuticals (Nasdaq: ALXN) reported that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2018 at 9:00 a.m., PT (12:00 p.m., ET) (Press release, Alexion, JAN 2, 2018, View Source [SID1234522810]). The Q&A breakout session will immediately follow the presentation at 9:30 a.m., PT (12:30 p.m., ET).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An audio webcast of the presentation and breakout session will be available live. You can access the webcast at: View Source An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

On January 2, 2018 Alkermes plc (NASDAQ: ALKS) reported that its corporate presentation will be webcast live at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2018 at 10:30 a.m. PT (1:30 p.m. ET/6:30 p.m. GMT) from the Westin St. Francis Hotel in San Francisco (Press release, Alkermes, JAN 2, 2018, View Source;p=RssLanding&cat=news&id=2324467 [SID1234522811]). The presentation will be followed by a question and answer session that will begin at 11:00 a.m. PT (2:00 p.m. ET/7:00 p.m. GMT). A webcast of both the presentation and question and answer session may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

On January 2, 2018 AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, reported that Paul C. Grint, M.D., Chief Executive Officer, will present a company overview at the 10th Annual Biotech Showcase, on Monday, January 8, 2018, at 9:30 a.m. PST, in San Francisco (Press release, AmpliPhi Biosciences, JAN 2, 2018, View Source [SID1234522812]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Events and Presentations page in the Investor Relations section of AmpliPhi’s website at www.ampliphibio.com.

On January 2, 2018 Array BioPharma Inc. (Nasdaq: ARRY) reported that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare Conference in San Francisco (Press release, Array BioPharma, JAN 2, 2018, View Source;p=RssLanding&cat=news&id=2324433 [SID1234522813]). The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Annual J.P. Morgan Healthcare Conference

Presenter: Ron Squarer, Chief Executive Officer, Array BioPharma

Date: Monday, January 8, 2018

Time: 4:00 p.m. Pacific Time

Location: Westin St. Francis Hotel, San Francisco

Webcast: View Source;p=irol-calendar

On January 2, 2018 Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), reported that Dr. André Choulika, Chairman and Chief Executive Officer of Cellectis, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 p.m. Pacific Time in the Elizabethan A/B room (Press release, Cellectis, JAN 2, 2018, View Source [SID1234522815]). A Q&A session will follow at 1:30 p.m. PT in the Sussex room. The conference will be held from January 8 to 11, 2018 at the Westin St. Francis Hotel in San Francisco, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of Cellectis presentation and subsequent breakout session, please visit View Source A replay of the webcast will be available on Cellectis website for 90 days.